BMO Capital Markets Reaffirms Outperform Rating for Ra Pharmaceuticals (RARX)

BMO Capital Markets reissued their outperform rating on shares of Ra Pharmaceuticals (NASDAQ:RARX) in a research report sent to investors on Monday morning, The Fly reports. The firm currently has a $34.00 target price on the stock, up from their prior target price of $31.00.

A number of other brokerages also recently weighed in on RARX. Zacks Investment Research upgraded shares of Ra Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, September 19th. Jefferies Group set a $25.00 price target on shares of Ra Pharmaceuticals and gave the company a buy rating in a research report on Friday, August 25th. Royal Bank Of Canada initiated coverage on shares of Ra Pharmaceuticals in a research report on Thursday, September 14th. They issued an outperform rating and a $21.00 price target on the stock. Finally, Credit Suisse Group increased their price target on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an outperform rating in a research report on Friday, November 10th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $23.20.

Shares of Ra Pharmaceuticals (NASDAQ RARX) traded down $0.52 during mid-day trading on Monday, hitting $7.45. 498,200 shares of the stock were exchanged, compared to its average volume of 133,109. Ra Pharmaceuticals has a 52 week low of $7.31 and a 52 week high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06). sell-side analysts forecast that Ra Pharmaceuticals will post -2.46 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in RARX. Candriam Luxembourg S.C.A. lifted its holdings in shares of Ra Pharmaceuticals by 43.2% during the third quarter. Candriam Luxembourg S.C.A. now owns 116,000 shares of the company’s stock worth $1,694,000 after buying an additional 35,000 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Ra Pharmaceuticals by 70.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock worth $409,000 after buying an additional 9,000 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Ra Pharmaceuticals by 33.7% during the second quarter. JPMorgan Chase & Co. now owns 199,900 shares of the company’s stock worth $3,746,000 after buying an additional 50,432 shares in the last quarter. Nationwide Fund Advisors lifted its holdings in shares of Ra Pharmaceuticals by 1,078.4% during the second quarter. Nationwide Fund Advisors now owns 32,842 shares of the company’s stock worth $615,000 after buying an additional 30,055 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Ra Pharmaceuticals during the third quarter worth $4,664,000. Hedge funds and other institutional investors own 69.64% of the company’s stock.

TRADEMARK VIOLATION WARNING: “BMO Capital Markets Reaffirms Outperform Rating for Ra Pharmaceuticals (RARX)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/07/bmo-capital-markets-reaffirms-outperform-rating-for-ra-pharmaceuticals-rarx.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

The Fly

Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply